Clinical trial NCT04126551: Mitochondrial Methylation in Type 2 Diabetes
Official title: Unraveling the Role of Mitochondrial DNA Methylation in Type 2 Diabetes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Overweight
Obesity
Diabetes Mellitus, Type 2
Insulin Resistance
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2019-10-15
Enrollment: 27
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Three groups of volunteers will be studied: 1) lean, healthy volunteers, 2) overweight/obese volunteers without type 2 diabetes, and 3) volunteers with type 2 diabetes

Brief summary: The overarching goal of this proposal is to determine whether DNA methylation of the mitochondrial DNA impairs mitochondrial function in insulin resistant states such as overweight/obesity and type 2 diabetes.

Detailed description: To determine whether differences in human skeletal muscle DNA methylation patterns in the mitochondrial and nuclear genome can explain the lower abundance of ETC and OXPHOS mRNA and protein observed in insulin resistant skeletal muscle of overweight/obese and type 2 diabetic participants. To determine whether patterns of human skeletal muscle DNA methylation in the mitochondrial and nuclear genome are predictive of ETC function. We will isolate skeletal muscle mitochondria from metabolically well-characterized lean insulin sensitive, overweight/obese insulin resistant nondiabetic and obese insulin resistant type 2 diabetic volunteers, and functionally evaluate each ETC complex (I - IV) and complex V (ATP synthase).

Eligibility criteria: Inclusion Criteria:

1. Subjects must be 21-55 years old
2. Body Mass Index:

   Lean, healthy BMI ≤25; Overweight,non-diabetic BMI 25-29.9; Obese, non-diabetic BMI 30-50; Type 2 Diabetes (per the American Diabetes Association criteria)
3. Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
4. Female subjects must be non-lactating and will be eligible only if they have a negative pregnancy test throughout the study period, and must agree to use acceptable birth control (hormonal contraceptives, barrier methods, have an intrauterine device, or surgical sterilization)
5. Subjects must have the following laboratory values:

   * Hematocrit ≥ 35 vol%
   * Serum creatinine ≤ 1.6 mg/dl
   * AST (SGOT) \< 2 times upper limit of normal
   * ALT (SGPT) \< 2 times upper limit of normal
   * Alkaline phosphatase \< 2 times upper limit of normal
   * Triglycerides \< 150 mg/dl for nondiabetics
   * Triglycerides \<300 for diabetics
   * INR ≤ 1.3
   * HbA1c ≤ 10

Exclusion Criteria:

1. Subjects must not be receiving any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on a stable dose of such agents for the past three months before entry into the study. Subjects must not be taking estrogens or other hormonal replacement therapy unless the subject has been on these agents on a stable dose for the prior three months. Subjects taking systemic glucocorticoids are excluded. Patients with type 2 diabetes will be excluded if they are taking thiazolidinediones.
2. Subjects receiving Gemfibrozil must not also be receiving a statin.
3. Subjects with a history of clinically significant heart disease (New York Heart Classification greater than grade II; more than non-specific ST-T wave changes on the EKG), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) will not be studied.
4. Recent systemic or pulmonary embolus, untreated high-risk proliferative retinopathy, recent retinal hemorrhage, uncontrolled hypertension, systolic BP\>160, diastolic BP\>95, autonomic neuropathy, resting heart rate \>100, electrolyte abnormalities.

Primary outcomes:
measure: Mitochondrial DNA methylation
timeFrame: 3 years
Secondary outcomes:
measure: Mitochondrial Function
timeFrame: 3 years
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Clinical and Translational Research Center (CaTS)
state: Arizona
Study officials:
affiliation: University of Arizona
name: Dawn K Coletta, PhD
role: PRINCIPAL_INVESTIGATOR
References: